Thu Sep 19 05:44:56 UTC 2024: ## Pyxis Oncology Outperforms Earth Science Tech Despite Higher Volatility

**Boston, MA & Miami, FL – September 19, 2024** – MarketBeat News analyzed two small-cap medical companies, Pyxis Oncology (NASDAQ:PYXS) and Earth Science Tech (OTCMKTS:ETST), to determine which stock offers a better investment opportunity.

While both companies are in the medical field, Pyxis Oncology stands out as the more favorable investment option. Despite having a higher beta, indicating greater volatility than the S&P 500, Pyxis Oncology boasts strong institutional ownership, higher potential upside according to analysts, and a focus on developing innovative cancer therapies.

Pyxis Oncology focuses on developing antibody-drug conjugates (ADCs) and immuno-oncology (IO) therapies for various cancers. Their lead product candidates, PYX-201 and PYX-106, are currently in Phase 1 clinical trials for treating relapsed or refractory solid tumors.

Earth Science Tech, on the other hand, operates in the health and wellness industry. They offer men’s health telemedicine services, a pharmacy, and supplements. Although Earth Science Tech wins out in seven of the ten factors analyzed, analysts believe Pyxis Oncology has a higher potential upside, currently estimated at 145.90%.

MarketBeat recommends investors considering Pyxis Oncology for their portfolio, given their potential for long-term growth and favorable analyst outlook.

Read More